{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA,IIIB\n(N2) Non-small Cell Lung Cancer","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-double-blind-placebo-and-active-comparator-controlled-clinical-study-of-adjuvant-v940-mrna-4157-plus-pembrolizumab-versus-adjuvant-placebo-plus-pembrolizumab-in-participants\/#breadcrumbitem"}]}